Condition
Immune Thrombocytopenia With Positive ANA Antibodies
Total Trials
3
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (3)
Trial Status
Recruiting3
Clinical Trials (3)
Showing 3 of 3 trials
NCT06479304Not ApplicableRecruitingPrimary
The Efficacy and Safety of HCQ Plus Pred in ANA Positive ITP
NCT06479317Not ApplicableRecruitingPrimary
The Efficacy and Safety of HCQ Plus DEX in ANA Positive ITP
NCT06479291Not ApplicableRecruitingPrimary
The Efficacy and Safety of HCQ Plus TPO-RA in ANA Positive ITP
Showing all 3 trials